Search Results - "Fong, C.C."

Competitor analysis and accounting of social networking site service companies in China by Steve Fong, C.C, Wong, John

“…Purpose - The purpose of this paper is to employ competitive analysis and accounting (CAA) spectrum to analyze the growth and development of social networking…”
Get full text

Strategic management accounting of social networking site service company in China by Steve Fong, C.C

“…Purpose - Social networking site (SNS) service is a popular cultural issue that affects communication methods and mannerisms. The purpose of this paper is to…”
Get full text

Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma With Bone Metastases: A Randomized First-Line Phase II Trial by Broom, Reuben J, Hinder, Victoria, Sharples, Katrina, Proctor, Janie, Duffey, Steven, Pollard, Stephanie, Fong, Peter C.C, Forgeson, Garry, Harris, Dean L, Jameson, Michael B, O'Donnell, Anne, North, Richard T, Deva, Sanjeev, Hanning, Fritha J, Grey, Andrew, Findlay, Michael P.N

“…Micro-Abstract This study prospectively evaluated the benefits of the addition of bone-specific therapy to targeted therapy in patients with renal cell…”
Get full text

Analysis of Molecular Cytogenetic Changes in Metastatic Renal Cell Carcinoma in the Setting of Everolimus Treatment: A Pilot Project by Caldwell, Imogen R, Oei, Paul, Ng, Daniel, Caudwell, Beth, Fong, Peter C.C, Broom, Reuben J

“…Micro-Abstract Currently there are no predictive biomarkers for preselecting patients with renal cancer who are more likely to benefit from mammalian target of…”
Get full text

iTRAQ-based proteomic profiling of the marine medaka (Oryzias melastigma) gonad exposed to BDE-47 by Fong, C.C., Shi, Y.F., Yu, W.K., Wei, F., van de Merwe, J.P., Chan, Alice K.Y., Ye, R., Au, Doris W.T., Wu, Rudolf S.S., Yang, M.S.

“…•We generate the protein expression profiles of marine medaka gonads upon BDE-47.•The protein expression profiles exerted dose- and sex-dependent…”
Get full text

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial by Agarwal, Neeraj, Azad, Arun A, Carles, Joan, Fay, Andre P, Matsubara, Nobuaki, Heinrich, Daniel, Szczylik, Cezary, De Giorgi, Ugo, Young Joung, Jae, Fong, Peter C C, Voog, Eric, Jones, Robert J, Shore, Neal D, Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G, Di Santo, Nicola, Zohren, Fabian, Fizazi, Karim

“…Co-inhibition of poly(ADP-ribose) polymerase (PARP) and androgen receptor activity might result in antitumour efficacy irrespective of alterations in DNA…”
Get full text

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial by Fizazi, Karim, Azad, Arun A., Matsubara, Nobuaki, Carles, Joan, Fay, Andre P., De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C. C., Voog, Eric, Jones, Robert J., Shore, Neal D., Dunshee, Curtis, Zschäbitz, Stefanie, Oldenburg, Jan, Ye, Dingwei, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Laird, A. Douglas, Zohren, Fabian, Agarwal, Neeraj

“…Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose)…”
Get full text

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study by Yu, Evan Y., Piulats, Josep M., Gravis, Gwenaelle, Fong, Peter C.C., Todenhöfer, Tilman, Laguerre, Brigitte, Arranz, Jose A., Oudard, Stephane, Massard, Christophe, Heinzelbecker, Julia, Nordquist, Luke T., Carles, Joan, Kolinsky, Michael P., Augustin, Marinela, Gurney, Howard, Tafreshi, Ali, Li, Xin Tong, Qiu, Ping, Poehlein, Christian H., Schloss, Charles, de Bono, Johann S.

“…The KEYNOTE-365 study assessed the efficacy and safety of pembrolizumab combination therapies in metastatic castration-resistant prostate cancer (mCRPC). In…”
Get full text

Clinical and serological resolution of pembrolizumab associated Sjögren’s syndrome: long-term follow-up by Clark, Hadleigh J, Fong, Peter C C, Ng, Kristine P L

Get full text

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study by Azad, Arun A., Fizazi, Karim, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschäbitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Lin, Xun, DeAnnuntis, Liza, Di Santo, Nicola, Zielinski, Michael A., Agarwal, Neeraj

“…This detailed analysis further characterizes the safety profile of talazoparib plus enzalutamide in the ongoing randomized, phase III TALAPRO-2 study in…”
Get full text

Post hoc analysis of rPFS and OS from the TALAPRO-2 (TP-2) study: Genomic subgroups based on likelihood of BRCA or HRR gene alteration status by Shore, Neal D., Agarwal, Neeraj, Azad, Arun, Carles, Joan, Fay, Andre P., Matsubara, Nobuaki, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Voog, Eric, Jones, Robert J, Dunshee, Curtis, Zschaebitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Laird, Douglas, Zohren, Fabian, Fizazi, Karim

“…136 Background: Prior to randomization in TP-2, patients (pts) (N=805; all-comers) were prospectively assessed for HRR gene alterations in tumor tissue and/or…”
Get full text

Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study by De Giorgi, Ugo, Azad, Arun, Fizazi, Karim, Matsubara, Nobuaki, Saad, Fred, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Cislo, Paul, Kirker, Melissa, Healy, Cynthia G., Niyazov, Alexander, Agarwal, Neeraj

“…116 Background: In TALAPRO-2 (NCT03395197), TALA +ENZA vs PBO + ENZA demonstrated significant improvement in radiographic progression-free survival, a…”
Get full text

Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E by Augustin, Marinela, Laguerre, Brigitte, Baldini, Capucine, Zedan, Ahmed H., Gonzalez-Billalabeitia, Enrique, Fong, Peter C.C., Zukov, Ruslan, Hammerer, Peter, Prentice, Mark, Shore, Neal D., Necchi, Andrea, Todenhöfer, Tilman, Kessler, Elizabeth R., Köse, Fatih, Gurney, Howard, Perez Valderrama, Begona, Zhu, Pengfei, Imai, Kentaro, liu, yingjie, McDermott, Raymond S.

“…148 Background: More efficacious treatment options are needed to extend survival and disease control for pts with mCRPC whose disease progressed after…”
Get full text

Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G by Fong, Peter C.C., Kwiatkowski, Mariusz, Mosca, Alessandra, Perez Valderrama, Begona, Huang, Yi-Hsiu, Zedan, Ahmed H., Kuc, Kamil, Wiechno, Pawel, Laguerre, Brigitte, Gonzalez-Billalabeitia, Enrique, Osipov, Mikhail, Sener Dede, Didem, Goh, Jeffrey, Daugaard, Gedske, Zhu, Pengfei, Imai, Kentaro, liu, yingjie, Arranz Arija, Jose Angel

“…149 Background: Novel therapeutic options to extend disease control and survival for pts with mCRPC whose disease progressed after docetaxel chemotherapy…”
Get full text

Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2 by Fizazi, Karim, Shore, Neal D., Fong, Peter C.C., Azad, Arun, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Dunshee, Curtis, Carles, Joan, Fay, Andre P., Cislo, Paul, Kirker, Melissa, Healy, Cynthia G., Niyazov, Alexander, Agarwal, Neeraj

“…109 Background: Cohort 2 of the TALAPRO-2 (NCT03395197) study demonstrated benefit in radiographic progression-free survival (rPFS) with talazoparib (TALA)…”
Get full text

Gender-specific transcriptional profiling of marine medaka (Oryzias melastigma) liver upon BDE-47 exposure by Yu, W.K., Shi, Y.F., Fong, C.C., Chen, Y., van de Merwe, J.P., Chan, Alice K.Y., Wei, F., Bo, J., Ye, R., Au, Doris W.T., Wu, Rudolf S.S., Yang, M.S.

“…Marine medaka (Oryzias melastigma) were exposed to 2,2′,4,4′-tetrabromodiphenyl ether (BDE-47) to investigate the gender-specific transcriptional profiles of…”
Get full text

Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2) by Agarwal, Neeraj, Azad, Arun, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Cislo, Paul, Chang, Jane, Healy, Cynthia G., Niyazov, Alexander, Fizazi, Karim

“…5013 Background: TALAPRO-2 (NCT03395197) showed statistically significant improvement in radiographic progression free survival with TALA + ENZA (n=402) vs PBO…”
Get full text

Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study by Azad, Arun, Fizazi, Karim, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Jones, Robert J., Zschaebitz, Stefanie, Oldenburg, Jan, Shore, Neal D., Dunshee, Curtis, Carles, Joan, Fay, Andre P., Lin, Xun, DeAnnuntis, Liza L, Di Santo, Nicola, Engelsberg, Arne, Agarwal, Neeraj

“…5053 Background: The phase 3 TALAPRO-2 study demonstrated a clinically meaningful and statistically significant improvement in radiographic progression-free…”
Get full text

Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study by Albiges, Laurence, Beckermann, Katy, Miller, Wilson H., Goh, Jeffrey C., Gajate, Pablo, Harris, Carole A., Suárez, Cristina, Peer, Avivit, Park, Se Hoon, Stadler, Walter Michael, Weickhardt, Andrew James, Faust, Guy, Fong, Peter C.C., Waddell, Tom, Venugopal, Balaji, Yin, Lina, Wang, Ding, Perini, Rodolfo F., Powles, Thomas

“…4553 Background: The oral HIF-2α inhibitor belzutifan demonstrated antitumor activity with manageable safety as monotherapy in pts with heavily pretreated…”
Get full text

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations by Fizazi, Karim, Azad, Arun, Matsubara, Nobuaki, Carles, Joan, Fay, Andre P., De Giorgi, Ugo, Joung, Jae Young, Fong, Peter C.C., Voog, Eric, Jones, Robert J., Shore, Neal D., Dunshee, Curtis, Zschaebitz, Stefanie, Oldenburg, Jan, Lin, Xun, Healy, Cynthia G., Di Santo, Nicola, Zohren, Fabian, Agarwal, Neeraj

“…5004 Background: TALAPRO-2 is the first phase 3 study to combine the poly(ADP-ribose) polymerase inhibitor TALA with the androgen receptor inhibitor ENZA in…”
Get full text